Rezolute, Inc.: management transactions · United States · SEC (Form 4)

About Rezolute, Inc.

Rezolute, Inc. (ticker: RZLT) is a United States-based biopharmaceutical company listed on Nasdaq, with headquarters in Redwood City, California. For French-, Belgian- and Swiss-based investors, the company fits squarely into the specialty rare-disease segment: it is focused on a medically underserved condition characterized by recurrent, sometimes severe hypoglycemia driven by hyperinsulinism. Rezolute is not a diversified pharma group; it is a late-stage clinical developer whose equity story is largely tied to execution in a narrow therapeutic area. The company traces its origins back to its former identity as AntriaBio, Inc., before adopting the Rezolute name in December 2017. Since then, management has sharpened the strategic focus around ersodetug, a fully human monoclonal antibody designed to bind allosterically to the insulin receptor and reduce receptor over-activation from insulin and related substances. In practical terms, the drug candidate is intended to address the dangerous glucose drops associated with hyperinsulinism, a condition that can be chronic, complex, and difficult to manage. Rezolute’s current pipeline is centered on two Phase 3 programs: congenital hyperinsulinism and tumor hyperinsulinism. This concentrated pipeline gives the company a clear scientific and commercial narrative, but it also creates binary development risk. Competitive positioning is therefore defined less by broad scale and more by potential first- or best-in-class differentiation in a rare disease space where clinical efficacy, durability, safety, and regulatory alignment are crucial. Recent news flow has been important for the investment case. In December 2025, the company disclosed topline results from the sunRIZE study. In March 2026, following a Type B meeting with the U.S. FDA, Rezolute said the agency encouraged submission of comprehensive data from sunRIZE and the ongoing open-label extension to help determine next steps. In May 2026, the company presented expanded analyses at the Pediatric Endocrine Society 2026 Annual Meeting, highlighting additional glucose-monitoring endpoints and ongoing patient exposure in the extension study. Geographically, Rezolute remains primarily anchored in the United States, with clinical operations conducted through study sites used in its development programs. For investors tracking U.S. small- and mid-cap biotech on Nasdaq, the company is best viewed as a catalyst-driven rare-disease story with meaningful upside potential, but also with material clinical and regulatory risk.